Cadrenal Therapeutics Inc. is a biopharmaceutical company. It focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. Cadrenal Therapeutics Inc. is based in PONTE VEDRA, Fla.
Info & Links
CEO
Quang Pham
Headquarters
822 A1A North, Suite 306 Ponte Vedra, FL 32082, UNITED STATES
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.